Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2019

View Archived Issues

Non-oncogene addiction to sirtuin in DLBCL

Favipiravir shows efficacy against Bourbon virus

Modification improves infliximab safety and response in RA

FDA accepts IND application for TAK-169

High rates of response seen with repotrectinib in fusion-positive NSCLC

Triumvira Immunologics cleared in U.S and Canada to conduct TAC01-CD19 studies

Dosing starts in phase I study of gene therapy to treat Danon disease

Vanflyta approved in Japan for the treatment of relapsed/refractory FLT3-ITD AML

Lenvatinib demonstrates promising antitumor activity and safety in phase II LEMON study in mCRC

Phase II results for lanreotide autogel 120 in inoperable malignant intestinal obstruction

Encouraging response rates seen for nanatinostat plus valganciclovir in EBV-associated lymphomas

Potential T2DM treatment HD-6277 well tolerated in first-in-human trial

Thioredoxin 1 fusion protein compositions described by Hallym University

Jounce initiates phase II trial of vopratelimab with ipilimumab in NSCLC or urothelial cancer

Suzhou Institute of Tongji University patents c-Met agonistic antibodies

FUD peptide targeting fibronectin patented by Wisconsin Alumni Research Foundation

Nanjing TransThera Biosciences identifies semicarbazide-sensitive amine oxidase inhibitors

Roche discovers monoglyceride lipase inhibitors

IQSEC1 gene mutations tied to intellectual disability and developmental delay

Miransertib studied in patients with PIK3CA-related overgrowth spectrum and Proteus syndrome

FDA approves Keytruda for metastatic SCLC after platinum and other prior therapy

Intuniv approved in Japan for adults with ADHD

Bevespi Aerosphere wins approval in Japan for COPD

Japan first to approve Breztri Aerosphere for COPD

Antitumor activity seen for acalabrutinib + pembrolizumab combination in relapsed/refractory DLBCL

CyTuVax reports results from phase II trial of HBAI-20 vaccine in hepatitis B nonresponders

Ultomiris approved in Japan for PNH

Therapix reports phase IIa interim data on THX-110 in patients with obstructive sleep apnea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...